Table 1 Baseline patients’ overview according to gender.
From: The effects of safinamide according to gender in Chinese parkinsonian patients
All population (n = 305) | Females (n = 128) | Males (n = 177) | p-value | ||
|---|---|---|---|---|---|
Age at enrollment (years) | Mean (SD) | 61.5 (9.2) | 69.4 (9.4) | 67.8 (9.7) | 0.6471 |
Race (n, %) | Chinese | 305 (100.0%) | 128 (100.0%) | 177 (100.0%) | – |
Diagnosis (n, %) | Idiopathic PD | 305 (100.0%) | 128 (100.0%) | 177 (100.0%) | – |
Disease duration (years) | Mean (SD) | 8.4 (5.0) | 8.5 (4.9) | 8.3 (4.8) | 0.5937 |
Hoehn and Yahr stage (n, %) | 1 | 11 (3.6%) | 7 (5.5%) | 4 (2.3%) | 0.1919 |
1.5 | 16 (5.2%) | 8 (6.3%) | 8 (4.5%) | ||
2 | 137 (44.9%) | 56 (43.8%) | 81 (45.8%) | ||
2.5 | 56 (18.4%) | 18 (14.1%) | 38 (21.5%) | ||
3 | 78 (25.6%) | 34 (26.6%) | 44 (24.9%) | ||
4 | 7 (2.3%) | 5 (3.9%) | 2 (1.1%) | ||
Total daily OFF time (h) | Mean (SD) | 5.7 (2.9) | 5.7 (2.8) | 5.8 (3.0) | 0.8564 |
Total daily ON time (h) | Mean (SD) | 10.2 (2.9) | 10.2 (3.0) | 10.1 (2.9) | 0.8595 |
Total daily ON time with no/non-troublesome dyskinesia (h) | Mean (SD) | 9.7 (2.8) | 9.9 (2.7) | 9.6 (2.8) | 0.4761 |
UPDRS total score (ON phase) | Mean (SD) | 46.0 (18.3) | 44.4 (17.9) | 47.1 (18.5) | 0.2062 |
UPDRS part II score (ON phase) | Mean (SD) | 12.0 (5.6) | 11.7 (6.0) | 12.2 (5.2) | 0.4991 |
UPDRS part III score (ON phase) | Mean (SD) | 27.1 (12.9) | 25.4 (11.9) | 28.2 (13.5) | 0.0649 |
PDQ-39 summary of index score | Mean (SD) | 24.7 (13.0) | 26.4 (13.5) | 23.5 (12.5) | 0.0600 |
Total daily levodopa dose (mg) | Mean (SD) | 510.0 (185.0) | 506.5 (210.0) | 518.5 (200.0) | 0.6200 |
Levodopa equivalent dose (mg) | Mean (SD) | 800.0 (340.0) | 786.5 (354.0) | 810.5 (330.0) | 0.4800 |
Concomitant antiparkinson drugs | Levodopa | 305 (100.0%) | 128 (100.0%) | 177 (100.0%) | – |
Pramipexole | 155 (100.0%) | 66 (51.5%) | 89 (50.2%) | ||
Entacapone | 110 (100.0%) | 45 (35.1%) | 65 (36.7%) | ||
Amantadine | 98 (100.0%) | 42 (32.8%) | 56 (31.6%) | ||
Anticholinergics | 42 (100.0%) | 17 (13.2%) | 25 (14.1%) |
